Drug Profile
JLP 1601
Alternative Names: JLP-1601Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cardiovascular disorders in South Korea (unspecified route)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders in South Korea
- 21 Mar 2016 Preclinical trials in Cardiovascular disorders in South Korea (unspecified route) prior to March 2016 (Jeil Pharmaceutical's pipeline, March 2016)